📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Ariad Pharmaceuticals

1.1 - Company Overview

Ariad Pharmaceuticals Logo

Ariad Pharmaceuticals

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of oncology medicines, focused on the discovery, development and commercialization of treatments for cancer patients, including Iclusig for certain types of leukemia targeting cancer cells with specific genetic mutations; based in Cambridge, Massachusetts.

Products and services

  • Development and commercialization of cancer medicines: A global-scale effort that develops and commercializes breakthrough oncology products, delivering cancer medicines to patients through cohesive, purpose-driven operations
  • Discovery of oncology medicines: An oncology-focused program that discovers breakthrough cancer medicines to transform patient lives, architected by a cohesive team committed to advancing therapies for cancer patients
  • Iclusig: A mutation-targeted medication for certain types of leukemia that targets cancer cells with specific genetic mutations, offering focused treatment for the indicated patient population

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Ariad Pharmaceuticals

Biovica Logo

Biovica

HQ: Sweden Website
  • Description: Provider of blood-based biomarker assays to help oncologists monitor cancer progression, including the DiviTum® TKa Test measuring cell proliferation from solid tumors, and pharma services offering TKa testing for dose-response information, patient selection, and treatment monitoring.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Biovica company profile →
Koya Medical Logo

Koya Medical

HQ: United States Website
  • Description: Provider of breakthrough treatments for lymphedema and venous diseases, as a transformative healthcare company.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Koya Medical company profile →
Deciphera Pharmaceuticals Logo

Deciphera Pharmaceuticals

HQ: United States Website
  • Description: Provider of kinase inhibitor–based cancer medicines leveraging a proprietary switch-control platform. Commercializes Ripretinib (QINLOCK) for advanced gastrointestinal stromal tumor after treatment with three or more kinase inhibitors, and develops a pipeline including Vimseltinib (CSF1R) for TGCT, DCC-3116 (ULK1/2) for cancers with RAS/RAF mutations, DCC-3084 (pan-RAF), and DCC-3009 (next‑gen KIT).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Deciphera Pharmaceuticals company profile →
Theraclone Sciences Logo

Theraclone Sciences

HQ: United States Website
  • Description: Provider of novel therapeutic antibodies and an antibody discovery platform for infectious diseases and inflammation. Offers a comprehensive screening technology to identify rare human monoclonal antibodies, HIV broadly neutralizing fully human antibodies licensed to Gilead for HIV-cure regimens, and platform technology licensed to OncoResponse for oncology.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Theraclone Sciences company profile →
Empirica Therapeutics Logo

Empirica Therapeutics

HQ: Canada Website
  • Description: Provider of therapeutic drugs focused on adoptive immunotherapies targeting aggressive, treatment-resistant cancers, including glioblastoma and brain metastasis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Empirica Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Ariad Pharmaceuticals

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Ariad Pharmaceuticals

2.2 - Growth funds investing in similar companies to Ariad Pharmaceuticals

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Ariad Pharmaceuticals

4.2 - Public trading comparable groups for Ariad Pharmaceuticals

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Ariad Pharmaceuticals

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Ariad Pharmaceuticals

What does Ariad Pharmaceuticals do?

Ariad Pharmaceuticals is a provider of oncology medicines, focused on the discovery, development and commercialization of treatments for cancer patients, including Iclusig for certain types of leukemia targeting cancer cells with specific genetic mutations; based in Cambridge, Massachusetts.

Who are Ariad Pharmaceuticals's competitors?

Ariad Pharmaceuticals's competitors and similar companies include Biovica, Koya Medical, Deciphera Pharmaceuticals, Theraclone Sciences, and Empirica Therapeutics.

Where is Ariad Pharmaceuticals headquartered?

Ariad Pharmaceuticals is headquartered in United States.

How many employees does Ariad Pharmaceuticals have?

Ariad Pharmaceuticals has 1,000 employees 🔒.

When was Ariad Pharmaceuticals founded?

Ariad Pharmaceuticals was founded in 2010 🔒.

What sector and industry vertical is Ariad Pharmaceuticals in?

Ariad Pharmaceuticals is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Ariad Pharmaceuticals

Who are the top strategic acquirers in Ariad Pharmaceuticals's sector and industry

Top strategic M&A buyers and acquirers in Ariad Pharmaceuticals's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Ariad Pharmaceuticals?

Top strategic M&A buyers groups and sectors for Ariad Pharmaceuticals include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Ariad Pharmaceuticals's sector and industry vertical

Which are the top PE firms investing in Ariad Pharmaceuticals's sector and industry vertical?

Top PE firms investing in Ariad Pharmaceuticals's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Ariad Pharmaceuticals's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Ariad Pharmaceuticals's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Ariad Pharmaceuticals's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Ariad Pharmaceuticals include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Ariad Pharmaceuticals's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Ariad Pharmaceuticals?

The key public trading comparables and valuation benchmarks for Ariad Pharmaceuticals include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Ariad Pharmaceuticals for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Ariad Pharmaceuticals with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Ariad Pharmaceuticals's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Ariad Pharmaceuticals with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Ariad Pharmaceuticals's' sector and industry vertical?

Access recent funding rounds and capital raises in Ariad Pharmaceuticals's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Ariad Pharmaceuticals

Launch login modal Launch register modal